Skip to main content

Table 2 Post-bronchodilator FEV1 % predicted at baseline

From: Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

FEV1, % predicted, n (%)

placebo

(n = 1524)

SAL

(n = 1521)

FP

(n = 1534)

SFC

(n = 1533)

total

(n = 6112)

< 30%

214 (14)

260 (17)

220 (14)

243 (16)

937 (15)

30% to < 50%

775 (51)

739 (49)

777 (51)

728 (47)

3019 (49)

50% to < 60%

347 (23)

335 (22)

329 (21)

349 (23)

1360 (22)

60% to < 70%

148 (10)

160 (11)

165 (11)

173 (11)

646 (11)

70% to < 80%

35 (2)

25 (2)

34 (2)

28 (2)

122 (2)

≥ 80%

5 (< 1)

2 (< 1)

9 (< 1)

12 (< 1)

28 (< 1)